Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: Results of a phase III trial
Autore:
Hale, A; Azorin, JM; Kasper, S; Maier, W; Syvalahti, E; Van der Burght, M; Sloth-Nielsen, M; Wehnert, A;
Indirizzi:
Univ Kent, Kent Res & Dev Ctr, Kent Inst Med & Hlth Sci, Canterbury, Kent,England Univ Kent Canterbury Kent England d & Hlth Sci, Canterbury, Kent,England Hop St Marguerite, Marseille, France Hop St Marguerite Marseille FranceHop St Marguerite, Marseille, France Univ Vienna, Dept Gen Psychiat, Vienna, Austria Univ Vienna Vienna Austria v Vienna, Dept Gen Psychiat, Vienna, Austria Klin & Poliklin Psychiat & Psychotherapie, Bonn, Germany Klin & Poliklin Psychiat & Psychotherapie Bonn Germany e, Bonn, Germany Dept Pharmacol & Clin Pharmacol, Turku, Finland Dept Pharmacol & Clin Pharmacol Turku Finland Pharmacol, Turku, Finland H Lundbeck AS, Copenhagen, Denmark H Lundbeck AS Copenhagen DenmarkH Lundbeck AS, Copenhagen, Denmark
Titolo Testata:
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
fascicolo: 1, volume: 4, anno: 2000,
pagine: 47 - 54
SICI:
1365-1501(200003)4:1<47:SIAWAL>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
ATYPICAL ANTIPSYCHOTIC-DRUGS; RISPERIDONE; HALOPERIDOL; DYSKINESIA; CLOZAPINE; SCALE; D-2;
Keywords:
antipsychotic agents; phase III clinical trial; sertindole; extrapyramidal symptoms; schizophrenia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Hale, A Univ Kent, Kent Res & Dev Ctr, Kent Inst Med & Hlth Sci, Canterbury, Kent,England Univ Kent Canterbury Kent England Sci, Canterbury, Kent,England
Citazione:
A. Hale et al., "Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: Results of a phase III trial", INT J PSYC, 4(1), 2000, pp. 47-54

Abstract

OBJECT: The objective of this double-blind, multicentre study was to evaluate four noses of sertindole and haloperidol 10 mg. METHOD: The 617 schizophrenic patients were randomized to receive sertindole 8, 16, 20 or 24 mg/day or haloperidol 10 mg/day. Patients were assessed for extrapyramidal symptoms (EPS) using the Simpson-Angus Scale (SAS) and Barnes Akathisia Scale (BAS), and for movement disorders using the Abnormal Involuntary Movement Scale (AIMS). RESULTS: Patients receiving haloperidol experienced significantly more EPSthan patients receiving sertindole, supporting observations mane in. previous studies. The incidence of adverse events was similar for all noses of sertindole. SAS and BAS scores were significantly worse in the haloperidol,group than in. the sertindole groups. There were significantly greater increases in mean QT(c) interval in the sertindole groups than in the haloperidol group. Sertindole did not cause sedation. CONCLUSIONS: Sertindole is well tolerated and does not cause the debilitating EPS associated with traditional antipsychotic drugs.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 07:22:51